Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Bacterial Inhibitor
4-Glycidyloxycarbazole is an antimicrobial agent that targets bacterial biofilm formation. It exhibits significant inhibitory activity against various bacterial strains, making it a valuable tool for studying bacterial behavior and infection control. This compound is useful in research applications focused on biofilm-related challenges in microbiology and infectious disease. -
Bacterial Inhibitor
KSK120 is a potent bacterial inhibitor targeting Chlamydia trachomatis (C. trachomatis). It disrupts the developmental cycle of the bacteria, leading to a reduction in the infectivity of progeny by targeting the glucose-6-phosphate metabolic pathway. KSK120 is particularly relevant for research into antimicrobial strategies, as its mechanism may involve inhibition of transcriptional processes, offering a novel approach for the development of targeted therapies against C. trachomatis infections. -
Bacterial Inhibitor
10-Isobutyryloxy-8,9-epoxythymol isobutyrate is a bacterial inhibitor derived from Inula helenium and Inula royleana root cultures, exhibiting moderate antimicrobial activity. This compound demonstrates efficacy against various pathogens, including Staphylococcus aureus, Enterococcus faecalis, Candida albicans, and Pseudomonas aeruginosa, with MIC values of 50, 250, 250, 250, and 1000 μg/mL, respectively. It serves as a valuable tool for research in antibacterial studies and the exploration of potential therapeutic agents. -
Bacterial Inhibitor
LolCDE-IN-3 is an inhibitor targeting the LolCDE complex, which plays a critical role in bacterial lipid A transport. This compound exhibits potent antibacterial activity, making it a valuable tool for studying bacterial physiology and pathogen resistance mechanisms. It is suitable for research applications focused on antibiotic development and the exploration of novel antibacterial strategies. -
Bacterial Inhibitor
OV-1, sheep is an alpha-helical antimicrobial peptide derived from the SMAP29 peptide of sheep, specifically designed to target and inhibit a range of antibiotic-resistant bacterial strains. This compound demonstrates significant efficacy against both mucoid and nonmucoid strains of Pseudomonas aeruginosa. OV-1, sheep is a valuable tool for research applications focusing on antimicrobial resistance and the development of peptide-based therapeutics. -
Bacterial Inhibitor
GSK729 is a selective inhibitor of EchA6, a critical enzyme involved in the fatty acid biosynthesis pathway of Mycobacterium tuberculosis. By specifically targeting and inhibiting EchA6, GSK729 demonstrates significant bactericidal activity, effectively obstructing the growth of the bacterium. This compound is valuable for research applications focused on the development of new therapeutic strategies against tuberculosis and exploring the role of fatty acid synthesis in bacterial pathogenesis. -
Bacterial Inhibitor
NBTIs-IN-4 is a potent bacterial inhibitor targeting DNA gyrase and topoisomerase IV in Gram-positive pathogens. It exhibits significant antibacterial activity while maintaining a low frequency of resistance. This compound is valuable for research applications aimed at understanding bacterial resistance mechanisms and developing new antibacterial therapies. -
Bacterial Inhibitor
BPH-1358 free base is a potent inhibitor of human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS), exhibiting IC50 values of 1.8 μM and 110 nM, respectively. This compound demonstrates significant antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of approximately 250 ng/mL. BPH-1358 free base is suitable for research applications aimed at understanding bacterial resistance mechanisms and developing novel antibacterial strategies. -
Bacterial Inhibitor
Lankacidin C 8-acetate is an antibiotic that targets bacterial pathogens through its antibacterial activity. This compound, part of the Lankacidin antibiotic group, exhibits significant inhibitory effects against specific bacterial strains. Additionally, Lankacidin C 8-acetate can react with various acyl donors to generate ester derivatives, highlighting its relevance in antibiotic synthesis and development for research applications. -
Bacterial Inhibitor
Macranthoside A is a triterpene glycoside that acts as a bacterial inhibitor. It demonstrates significant antimicrobial activity, making it a useful compound for research applications aimed at studying bacterial infections and evaluating potential therapeutic agents against microbial resistance. -
Bacterial Inhibitor
I-A09 is a bacterial inhibitor that demonstrates significant antitubercular activity against Mycobacterium tuberculosis H37Rv. This compound and its derivatives, particularly the 1,2,3-triazole-adamantylacetamide hybrids synthesized via copper-catalyzed click chemistry, display enhanced efficacy with a minimum inhibitory concentration (MIC) as low as 3.12 μg/mL. These novel analogues, particularly N-(1-adamantan-1-yl)-2-(4-(phenanthren-2-yl)-1H-1,2,3-triazol-1-yl)acetamide (5t), have applications in research focused on tuberculosis treatment and the development of new antitubercular agents. -
Bacterial Inhibitor
Antibacterial Agent 95 is a potent bacterial inhibitor with a primary target of Mycobacterium tuberculosis. Demonstrating a minimum inhibitory concentration (MIC) as low as 0.3 μM against the reference strain H37Rv, this 2-(quinoline-4-methoxy)acetamide compound effectively inhibits the growth of Mycobacterium tuberculosis in macrophage models of tuberculosis infection. Its exceptional activity makes it a valuable tool for research in antitubercular drug development. -
Bacterial Inhibitor
Pelagiomicin A is a phenazine antibiotic with a primary mechanism targeting bacterial cell functions. This compound demonstrates significant antibacterial activity against both Gram-positive and Gram-negative bacteria, making it a valuable tool for research in microbial resistance. Additionally, Pelagiomicin A has shown promising antitumor effects in vitro and in vivo, underscoring its potential applications in cancer research. Its structure has been elucidated through a combination of spectroscopic data and synthesis techniques, contributing to the understanding of its biological properties. -
DHPS Inhibitor
Dihydropteroate synthase-IN-1 is a potent inhibitor of dihydropteroate synthase (DHPS), primarily targeting the folate biosynthesis pathway. This compound exhibits significant antimicrobial and antifungal properties, making it valuable for research in microbial resistance and pathogenicity studies. Additionally, Dihydropteroate synthase-IN-1 has implications in diagnostics as a potential radio imaging agent, advancing the exploration of therapeutic interventions. -
Bacterial Inhibitor
2'-Hydroxy-2-methoxychalcone acts as a bacterial inhibitor, demonstrating significant antimicrobial activity against various bacterial strains. This synthetic chalcone derivative is valuable for research in understanding bacterial resistance mechanisms and developing new antimicrobial agents. Its structural properties facilitate the exploration of structure-activity relationships in the field of medicinal chemistry. -
Bacterial Inhibitor
Chinfloxacin is a bacterial inhibitor that exerts antibacterial activity against a range of clinical isolates in vitro. Demonstrating a concentration-dependent bactericidal effect, Chinfloxacin shares antibacterial efficacy comparable to that of moxifloxacin. This compound is suitable for research applications focused on bacterial pathogenicity and the development of new antimicrobial agents. -
Bacterial Inhibitor
Phenethicillin potassium is a β-lactam antibiotic that targets bacterial cell wall synthesis by inhibiting penicillin-binding proteins. It demonstrates significant antibacterial activity against a range of Gram-positive bacteria, making it valuable in research applications focused on antimicrobial resistance and the mechanistic understanding of bacterial susceptibility. Its characteristic action profile facilitates studies in microbiology and pharmacology, providing insights into antibiotic efficacy and resistance mechanisms. -
Bacterial Inhibitor
Hikizimycin is a potent antibacterial agent that targets bacterial cell growth and division. This natural product exhibits significant antibacterial activity, making it a valuable tool for research focused on bacterial infections and their treatment. Its unique mechanism of action offers insights into new therapeutic strategies for combating antibiotic resistance. -
Bacterial Inhibitor
Antibacterial Agent 28 is a bacterial inhibitor with a mechanism targeting the growth and proliferation of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA). It exhibits antimicrobial activity with minimum inhibitory concentrations (MICs) ranging from 0.5 to 2 μg/mL. This reagent holds promise for research applications aimed at developing new treatments against resistant bacterial infections. -
MabA (FabG1) Inhibitor
FabG1-IN-1 is a selective inhibitor of MabA (FabG1), exhibiting an IC50 of 38 µM. This compound effectively impedes the enzymatic activity of FabG1, playing a crucial role in fatty acid biosynthesis. FabG1-IN-1 is applicable in research focusing on metabolic pathways and the development of antifungal therapies targeting lipid synthesis. -
Bacterial Inhibitor
β-L-Gulopyranosyl-caldarchaetidyl-glycerol (GuCGp) is a polar lipid compound targeting bacterial membranes. Its role in the lipid composition of thermoacidophilic bacteria is crucial for understanding bacterial adaptation to varying environmental conditions. This compound is valuable for research applications focused on microbial physiology and membrane biochemistry. -
Bacterial Inhibitor
Ceratotoxin B is an antibacterial peptide derived from the sexually mature females of Ceratitis capitata. It exhibits lytic and antibacterial activity, making it a valuable research tool for studying bacterial inhibition and antimicrobial mechanisms. This peptide can be utilized in studies aimed at understanding bacterial resistance and the development of novel antibacterial agents. -
Bacterial Inhibitor
TP0586352 is a potent LpxC inhibitor specifically designed to target bacterial pathogens, including carbapenem-resistant Klebsiella pneumoniae. This compound exhibits significant antibacterial activity while maintaining a favorable safety profile, as it does not pose cardiovascular risks. Additionally, TP0586352 features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions for further chemical modifications. -
Bacterial Inhibitor
Propioxatin B is a tricyclic sesquiterpenoid compound that acts as a bacterial inhibitor. This compound demonstrates significant anti-tuberculosis activity, exhibiting effectiveness against various drug-resistant Mycobacterium tuberculosis strains. In silico docking studies indicate that Propioxatin B binds with bacterial DNA gyrase, suggesting a targeted mechanism of action and potential safety in in vivo applications. -
Bacterial Inhibitor
Drimentine A is a terpenylated diketopiperazine that acts as a bacterial inhibitor, originally isolated from Actinomycete bacteria. It exhibits significant antibacterial activity, making it a valuable tool in microbiological studies. This compound is primarily utilized in research involving bacterial pathogenesis and the development of antimicrobial agents. Unlike its analogs Drimentine B and C, Drimentine A does not possess anticancer activity. -
HIV Inhibitor Prodrug
HIV-IN-13 prodrug is designed as a prodrug of an HIV inhibitor, engaging specifically with viral components upon conversion. In the presence of glutathione (GSH), this compound exhibits significant antiviral activity, demonstrating EC50 values of 10 μM and 8.2 μM against HIV-1 at concentrations of 1 mM and 2 mM GSH, respectively. This prodrug serves as a valuable tool for research focused on HIV infection and therapeutic development. -
HIV-1 Inhibitor
NB-64 is an orally active inhibitor of HIV-1 that targets viral replication. Its significant antiviral activity makes it a valuable tool for research into HIV infections and the development of therapeutic strategies. This compound contributes to a better understanding of HIV pathogenesis and potential treatment options. -
HIV Inhibitor
PNU-142721 is a reverse transcriptase inhibitor that targets HIV by effectively inhibiting various type I variants. This compound serves as a valuable tool in HIV research, particularly in the study of viral replication and resistance mechanisms. Its dual function as a PXR agonist further enhances its relevance in investigating drug metabolism and therapeutic strategies against HIV. -
HIV Integrase Inhibitor
Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies. -
HIV-1 Integrase Inhibitor
Integracin B is a potent inhibitor targeting HIV-1 integrase through a dimeric alkyl aromatic structure. It effectively inhibits both the coupled and strand transfer activities of the integrase, making it a valuable tool for studying HIV-1 replication and integration processes. This compound is suitable for research applications focused on antiviral drug development and the mechanistic understanding of integrase-mediated viral entry. -
HIV Inhibitor
HIV-1 Inhibitor-9 is a potent inhibitor targeting HIV-1, effectively inhibiting both wild-type and various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strains at low nanomolar concentrations. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV treatment and drug resistance mechanisms. Its efficacy against resistant strains supports its potential use in therapeutic studies and drug development efforts aimed at combating HIV-1 infection. -
HIV Inhibitor
Tripterifordin is a potent inhibitor of HIV replication, specifically targeting H9 lymphocyte cells. It demonstrates significant anti-HIV activity with an EC50 value of 3100 nM. This compound is valuable for research applications aimed at understanding HIV pathogenesis and developing therapeutic strategies against HIV infection. -
HIV Inhibitor
UK-88947 hydrochloride is a potent HIV protease inhibitor, primarily targeting HIV-1 replication. It effectively disrupts the early stages of the viral life cycle when administered to cells prior to infection. Additionally, UK-88947 hydrochloride inhibits viral protease activity during infection, thereby significantly impacting viral replication. This compound is valuable for research focused on developing therapeutic strategies against HIV. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
HIV-1 Inhibitor
HIV-1 Inhibitor-29 is a potent inhibitor targeting the HIV-1 virus, demonstrating an EC50 of 2.18 μM against the HIV-1 IIIB strain. This compound exhibits significant anti-resistance properties against the F227L/V106A mutant strain, with an EC50 of 0.974 μM, while maintaining low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 Inhibitor-29 is a valuable tool for research focused on AIDS and HIV-1 therapeutic development. -
HIV-1 Inhibitor
NNRT-IN-1 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV-1. This compound demonstrates significant anti-resistance efficacy, effectively inhibiting wild-type HIV-1 as well as five mutant strains, with EC50 values in the nanomolar range. Additionally, NNRT-IN-1 exhibits favorable pharmacokinetic properties, making it a valuable tool for research applications in HIV therapeutics. -
HIV Inhibitor
(+)-Carbovir is a nucleoside analog specifically designed to inhibit human immunodeficiency virus type 1 (HIV-1). Its enhanced chemical and metabolic stability contributes to its antiviral efficacy. This compound serves as a valuable tool in AIDS research, facilitating studies aimed at understanding and combating HIV infection. -
HIV-1 RT Inhibitor
Tivirapine is a non-nucleoside inhibitor targeting HIV-1 reverse transcriptase (RT), demonstrating potent antiviral activity with an EC50 value of 4 nM. This compound effectively inhibits the Y181C mutant of HIV-1 RT, offering a valuable tool for studying drug resistance mechanisms and evaluating therapeutic strategies against HIV-1 infection. Its application is relevant in both basic research and development of novel antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-64 (Compound 7c) is a potent antagonist targeting HIV-1, demonstrating effective inhibition of both wild-type and resistant mutants, specifically E138K/Q148K and G140S/Q148R, with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound exhibits significant antiviral activity, making it a valuable tool for AIDS research and studies focused on HIV-1 resistance mechanisms. -
HIV-1 Inhibitor
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1 with an EC50 of 1.9 nM, demonstrating potent antiviral activity. This compound exhibits minimal interaction with cytochrome P450 enzymes, with IC50 values of 5.16 μM for CYP2C9 and 4.51 μM for CYP2C19, indicating its favorable profile for therapeutic applications. Notably, HIV-1 inhibitor-40 shows no significant acute toxicity in vivo, making it a promising candidate for further research in HIV treatment. -
HIV Inhibitor
Influenza antiviral conjugate-1 (INT-2) is an HIV inhibitor that exhibits potent cell fusion inhibition. This compound serves as a click chemistry reagent, featuring an alkyne group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in biological research allows for the development of innovative therapeutic strategies and the study of viral entry mechanisms. -
HIV REV/RRE Interaction Inhibitor
Niruriside is an inhibitor of the HIV REV/RRE complex, specifically targeting the interaction between the HIV REV protein and RRE RNA with an IC50 of 3.3 μM. This compound exhibits selectivity, showing no significant effects on the unrelated R17 capsid protein/operator RNA binding system. While Niruriside does not protect CEM-SS cells from acute HIV-1 infection, it serves as a valuable tool for investigating the mechanisms of HIV infection and the role of the REV/RRE interaction in viral replication and pathogenesis. -
HIV-1 Inhibitor
L 696229 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), demonstrating significant antiviral activity. This compound is primarily utilized in the study of HIV replication and the development of antiretroviral therapies, offering insights into viral resistance mechanisms and potential therapeutic interventions. Its specificity for RT makes it a valuable tool in HIV research and drug discovery. -
HIV-1 Inhibitor
Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and functions as a prodrug for Amprenavir. Upon administration, it is hydrolyzed by cell phosphatases in the intestinal epithelium to release Amprenavir, which inhibits HIV-1 protease by binding to its active site. This binding prevents the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the maturation of infectious virus particles. Fosamprenavir sodium is valuable for research on human immunodeficiency virus (HIV-1) infection. -
HIV-1 Inhibitor
HIV-1 inhibitor-35 is a potent inhibitor of HIV-1, exhibiting EC50 values of 80 nM and 70 nM against LTR and CMV in HEK293 cells, respectively. This compound also demonstrates cytotoxic activity against HepG2 liver cancer cells, with a CC50 of 40 nM. HIV-1 inhibitor-35 is suitable for research applications in HIV-1 latency reversal and antiviral therapeutic investigations. -
HIV Inhibitor
GB-1a is a biflavanone that functions as an inhibitor of HIV-1 reverse transcriptase, demonstrating an IC50 value of 236 μM and an EC50 of 38.0 μM for HIV-1 replication. This compound effectively prevents the conversion of HIV-1 genomic RNA into DNA, making it a valuable tool for research on AIDS and HIV-1 infection. Additionally, GB-1a can be naturally sourced from the heartwood of Garcinia multiflora Champ, further emphasizing its potential for biological study. -
HIV-1 Inhibitor
AIC-292 is a selective inhibitor of HIV-1 nonnucleoside reverse transcriptase, demonstrating potent antiviral activity against wild-type HIV-1 laboratory strains at low nanomolar concentrations. This compound exhibits significant in vivo efficacy in mouse xenograft models, making it a valuable tool for research into HIV-1 infection and antiretroviral therapies. AIC-292 may aid in the development of innovative therapeutic strategies targeting HIV-1. -
HIV Inhibitor
HIV-1 inhibitor-38 is a potent HIV-1 inhibitor that exhibits effective antiviral activity against the virus responsible for HIV/AIDS. Its unique mechanism of action positions it as a potential candidate for further development as a latency-reversing agent, making it a valuable tool in HIV research and therapeutic investigation. This compound is particularly relevant for studies focused on viral eradication and understanding HIV latency. -
HIV-1 Inhibitor
HIV-IN-5 is a potent HIV-1 inhibitor that targets the non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP). It exhibits an IC50 value of 0.16 μM for inhibiting viral replication and demonstrates interference with HIV DNA-dependent DNA polymerization activity with an IC50 of 2.18 μM. This compound is valuable for research focused on HIV-1 antiviral mechanisms and the development of therapeutic agents targeting HIV replication. -
HIV-1 Inhibitor
HIV-1 Inhibitor-13 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. With an IC50 of 0.14 μM against HIV-1 reverse transcriptase, it demonstrates significant antiviral activity. This compound also exhibits effectiveness against various HIV-1 resistant strains, with EC50 values ranging from 2.85 to 18.0 nM, making it a valuable tool for HIV research and therapeutics development.
